- Cinfa introduces Rosvacor (Rosuvastatin) to the Qatari market, providing a treatment for dyslipidemia and prevention of cardiovascular diseases.
- Dyslipidemia and cardiovascular diseases are significant health challenges in the Middle East, with dyslipidemia alone responsible for approximately 40% of all deaths in the UAE1,2.
- Cinfa reaffirms its commitment to the health and well-being of the population in Qatar and the Middle East region. “Everything related to ischemic heart disease treatment, diabetes, hypertension, among others, constitutes the core of our strategy in the region” has emphasized Franc Vives, Chief International Officer at Cinfa.
The European pharmaceutical laboratory Cinfa has launched its new product Rosvacor (Rosuvastatin) in Qatar. This marks an important milestone in Cinfa’s expansion in the cardiometabolic area, offering new therapeutic options for dyslipidemia and prevention of cardiovascular diseases. Rosvacor is available in doses of 5mg, 10mg, and 20mg.
Cinfa has carried out this launch in response to the increasing prevalence of dyslipidemia and cardiovascular events in the Middle East, a region where these diseases represent a significant public health challenge.
Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ACD), which includes ischemic heart disease (IHD) and strokes. In the UAE, IHD and strokes are leading causes of premature death, responsible for approximately 40% of all deaths in the country. Effective management of dyslipidemia is crucial, as it can significantly reduce the progression of atherosclerosis and associated cardiovascular diseases.
Rosuvastatin, the key molecule in the treatment of dyslipidemia, has been shown to be effective in reducing LDL cholesterol, thus contributing to the prevention of cardiovascular diseases. According to the WHO, a 10% reduction in serum cholesterol levels can halve the risk of IHD in 40-year-old men over five years, underscoring the importance of medications like Rosvacor in managing dyslipidemia.
Strengthening the Cardiometabolic Portfolio
The addition of Rosvacor expands Cinfa’s cardiometabolic portfolio in Qatar, which already includes the following medicines:
- Atorcor (Atorvastatin)
- Vanguard (Valsartan)
- Vanguard Plus (Valsartan Hydrochlorothiazide)
- Olmepress (Olmesartan)
- Co-Olmepress (Olmesartan Hydrochlorothiazide)
- Olmedine (Olmesartan Amlodipine)
- Zetmol (Ezetimibe)
Cinfa’s strategy in the region focuses on addressing the alarming rise in diseases such as diabetes, hypertension, and other cardiovascular disorders, both in the Western and Eastern worlds. Franc Vives, Chief International Officer at Cinfa, has emphasized the importance of focusing on these areas to provide effective solutions to patients, and has stated, “everything related to ischemic heart disease treatment, diabetes, hypertension, among others, constitutes the core of our strategy in the region“. And has added that “this approach is clearly reflected in the launch of Rosvacor and the ongoing expansion of our cardiometabolic product portfolio in Qatar. According to our mission of improving the health and well-being of patients in Qatar and beyond, always focused on high quality, safe and effective medicines and health solutions.”
ABOUT CINFA
Cinfa, the leading Spanish pharmaceutical company, stands out as number one in units and values in the Spanish market. With over 55 years of experience, the group has a team of more than 2,200 professionals. Their commitment to health transcends borders, with a presence in over 100 countries. Cinfa provides accessible and high-quality pharmaceutical solutions, merging expertise, innovation, and a strong commitment to global well-being.
For more information
Lucía López: Lucia.lopez@sprim.com
Mireia Castro: Mireia.castro@sprim.com
Mary Aouad: Mary.aouad@sprim.com
1 Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit. https://link.springer.com/article/10.1007/s12325-023-02529-7
2 Dyslipidemia prevalence and associated risk factors in the United Arab Emirates: a population-based study. https://bmjopen.bmj.com/content/9/11/e031969
